Inhibition of Amine Oxidases by the Histamine-1 Receptor Antagonist Hydroxyzine

Total Page:16

File Type:pdf, Size:1020Kb

Inhibition of Amine Oxidases by the Histamine-1 Receptor Antagonist Hydroxyzine J Neural Transm (2006) [Suppl] 71: 105–112 # Springer-Verlag 2006 Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine J. O’Sullivan1;2, M. I. O’Sullivan2, K. F. Tipton1, G. Davey1 1 Department of Biochemistry, and 2 Dublin Dental School and Hospital, Trinity College, Dublin, Ireland Summary The effects of the drug hydroxyzine on the activities of the rat amine oxidases, as they are not inhibited by the mono- liver monoamine oxidases (EC 1.4.3.6; MAO) and the membrane-bound amine oxidase (MAO; EC 1.4.3.6) inhibitor clorgyline. and soluble forms of bovine semicarbazide-sensitive amine oxidase (EC 1.4.3.6; SSAO) were studied. Hydroxyzine was found to be a competitive They are a ubiquitous group of enzymes found in plants, inhibitorofMAO-B(Ki 38 mM), whereas it had a low potency towards animals and microbes (Lewinsohn, 1984; Callingham et al., > MAO-A (IC50 630 mM). Although it was a relatively potent competitive 1995; Lyles, 1996; Houen, 1999). Most mammalian spe- inhibitor of bovine plasma SSAO (K 1.5 mM), it was a weak inhibitor of i cies contain a soluble form of SSAO in the blood plasma the membrane-bound form of the enzyme from bovine lung (IC50 1mM). These findings extend our knowledge of the drug binding capabilities of the plus a membrane bound form of the enzyme that has a amine oxidases and suggest that these interactions may contribute to the relatively high activity in cardiovascular tissue, lung and complex actions of this drug. adipocytes (Boomsma et al., 2000; Lyles, 1995, 1996). Abbreviations: MAO monoamine oxidase, SSAO semicarbazide-sensitive Although the physiological functions of SSAO are by amine oxidase. no means fully understood, a primary role of SSAO is believed to be the scavenging of primary amines, either Introduction endogenous or xenobiotic (Tipton and Strolin Benedetti, 2001). The active site of the membrane bound form of The semicarbazide sensitive amine oxidases (SSAO) be- the enzyme appears to be externally facing, thus allowing long to the copper-containing group of amine oxidases the metabolism of extracellular amines. Methylamine and (EC 1.4.3.6; amine: oxygen oxidoreductase (deaminating) aminoacetone are specific substrates for SSAO, in that (copper containing)). They catalyse the oxidative de- MAO does not oxidise them (Lyles and Chalmers, 1992; amination of primary amines according to the overall reaction: Lizcano et al., 1994). SSAO and MAO, which is an in- tracellular enzyme, have been shown to work in concert RCH2NH2 þ O2 þ H2O ! RCHO þ NH3 þ H2O2: to facilitate the removal of tyramine in the isolated per- fused mesenteric arterial bed of the rat (Elliott et al., Their sensitivity to inhibition by semicarbazide and other 1989). The metabolism of dopamine may also involve carbonyl reagents results from the presence of a 3,4,6,tri- both SSAO and MAO, as shown in rat vas deferens (Lizcano hydroxyphenylalanine (TOPA) residue that serves as a co- et al., 1991). factor in the reaction. Several other functions of SSAO have been identified They have been known by several different names, (O’Sullivan et al., 2004; Tipton et al., 2003, for reviews). including benzylamine oxidase, owing to their preference At least in some tissues, it functions as a vascular-adhesion for benzylamine as a substrate, and clorgyline-resistant protein (vascular-adhesion protein-1; VAP-1) (Jalkanen and Salmi, 2001). It may also modulate cellular glucose trans- port by stimulating membrane glucose transporter re- Correspondence: Dr. J. O’Sullivan, Department of Biochemistry, Trinity College, Dublin 2, Ireland cruitment (Enrique-Tarancon et al., 1998, 2000). Roles e-mail: [email protected] for SSAO=VAP-1 have also been identified in adipocyte 106 J. O’Sullivan et al. Fig. 1. Chemical structure of hydroxyzine (2-[2-[4-[(4-chloro- phenyl)phenylmethyl]-1-piperazinyl]ethoxy]ethanol) development (Mercier et al., 2001) and in extracellular selectivity as an antagonist of the histamine H-1 receptor matrix formation (Langford et al., 2002; Gokturk et al., resulting in a reduction in sedation and brain penetration 2003). It appears that SSAO, may also function as a (Gillard et al., 2001). drug-binding protein. Imidazolines, such as amiloride, Since, histamine is a substrate for semicarbazide-sensi- and guanidine compounds, which are used clinically, as tive amine oxidase whereas MAO-B oxidizes its metabolite diuretic and hypertensive agents have been shown to bind NT-methylhistamine, we have investigated the possibility to MAO, SSAO and other amine oxidases (Mu et al., 1994; that hydroxyzine, might interact with these amine oxidases. Remaury et al., 2000; Holt et al., 2004). However the phy- siological significance of these drug-binding sites remains obscure (e.g., Eglen et al., 1988). Materials and methods The heterocyclic piperazine derivative hydroxyzine 2- [7-14C] Benzylamine hydrochloride (Specific activity 59 mCi=mmol), 5- [2-[4-[(4-chlorophenyl)phenyl-methyl]-1-piperazinyl]eth- Hydoxy [side-chain 2-14C]tryptamine creatine sulphate (Specific activity oxy]ethanol) (Fig. 1) is a histamine-1 receptor antagonist, 57 mCi=mmol) and 2-Phenylethylamine[ethyl-1-14C]hydrochloride (Spe- = with anticholinergic properties, which has a wide variety of cific activity 57 mCi mmol) were from Amersham. l-Deprenyl HCl was from Fluka and unlabelled substrates and other chemicals were from Sigma. therapeutic applications, including the treatment of allergic Rat liver mitochondria, prepared as previously described (Fowler and skin disorders and the control the nausea and vomiting Tipton, 1981) were used as the source of MAO. Bovine lung microsomes caused by various conditions, including motion sickness. were prepared as a source of membrane-bound SSAO (Lizcano et al., 1998) and bovine plasma SSAO was from Sigma. It is also used as a tranquilliser for the symptomatic man- More highly purified bovine plasma SSAO was prepared by a modifica- agement of conditions, such as generalised anxiety disorder tion of the procedure of Wang et al. (1994). 10 L of bovine blood were (GAD) and the tension associated with psychoneuroses mixed with 1 L of 2.5% sodium citrate solution and centrifuged at 3000 g for 20 min. Ammonium sulphate was added, with continuous stirring, to 4 L of (Lader et al., 1998; Ferreri and Hantouche, 1988), as well the supernatant to give 35% saturation. Stirring was continued for 2 h as in the treatment of the symptoms of alcohol withdrawal. before centrifugation at 10,000 g for 20 min. The supernatant was retained It is also used in the management of pruritis associated with and ammonium sulphate was added, with continuous stirring, to give 55% allergic conditions, such as chronic urticaria and histamine- saturation. Stirring was continued for 30 min before centrifugation at 10,000 g for 20 min. The precipitate taken up in 200 ml of 100 mM potas- mediated pruritus. Hydroxyzine has been shown to inhibit sium phosphate buffer, pH 7.2 and applied, at a flow rate of 150 ml=h, to a neurogenic mast-cell activation by a mechanism that Q-Sepharose column (30 Â2.5 cm), which had been equilibrated with is unrelated to its H-1 receptor antagonistic properties 10 mM potassium phosphate buffer, pH 7.5. After washing with 500 ml of the 10 mM phosphate buffer, SSAO was eluted, at a flow rate of 150 ml=h, (Minogiannis et al., 1998). It has also been shown to inhibit with a linear concentration gradient from 0.05 to 0.35 M NaCl in the experimental allergic encephalomyelitis and the associated same buffer. Fractions with a specific activity equal to or higher than brain mast cell activation and may also be effective in 0.4 mmol=min=mg protein were pooled, mixed with an equal volume = of 100 mM potassium phosphate buffer, pH 7.2, and applied to a Con the prevention of relapsing remitting multiple sclerosis A-Sepharose column (30 Â2.0 cm) that had been equilibrated with the same (Dimitriadou et al., 2000). buffer. The column was washed with 500 ml of 100 mM phosphate buffer Cetirizine, the carboxylic acid metabolite of hydroxy- and then with 300 ml of 20 mM methyl-a-D-glucopyranoside in that buffer zine, may also suppress inflammatory responses, as it pos- before the SSAO was eluted with 200 ml of 0.5 M methyl-a-D-mannopyr- anoside in the same potassium buffer. Fractions (6 ml) with specific activ- sesses an ability to inhibit both macrophage inhibitory ities equal or higher than 0.95 mmol=min=mg were pooled and applied to a factor (MIF) and IL-8 production (Shimizu et al., 2004; Q-Sepharose (30Â2.5 cm) column, previously equilibrated with 20 mM Giustizieri et al., 2004). It has been also been suggested to potassium phosphate buffer (pH 6.8). The column was then washed with 300 ml of the buffer and eluted with a continuous gradient from 0.05 to be effective against autoimmune diseases (Namazi, 2004). 0.35 M NaCl in that. The fractions with SSAO specific activity higher than The carboxyl group results in this derivative having high equal or higher than 15 mmol=min=mg protein were then pooled, dialysed Amine oxidase inhibition by hydroxyzine 107 against 20 mM potassium phosphate buffer, pH 6.8, for 6 h and stored in substrate by the radiochemical method of Tipton et al. (2000) or by a mod- aliquots of 300 ml in 20% glycerol at À20C. ification of the method of Tabor et al. (1954). The standard reaction mixture contained 50 mM potassium phosphate buffer, pH 7.2, and 0.024 mg=ml SSAO in a final volume of 1 ml. The reaction was initiated by the addition Assay of SSAO and MAO activities of the substrate benzylamine and the rate of change of absorbance at 250 nm All enzyme assays were performed at 37C and at pH 7.2, unless other- was monitored using a Cary 300-Biospectrophotometer.
Recommended publications
  • Aldrich FT-IR Collection Edition I Library
    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0318437 A1 Gaeta Et Al
    US 20090318437A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0318437 A1 Gaeta et al. (43) Pub. Date: Dec. 24, 2009 (54) SUBSTITUTED PYRAZOLO15-APYRIDINE (60) Provisional application No. 60/811,604, filed on Jun. COMPOUNDS AND THER METHODS OF 6, 2006. USE (76) Inventors: Federico C.A. Gaeta, Mountain Publication Classification View, CA (US); Matthew Gross, (51) Int. Cl. Vallejo, CA (US); Kirk W. A63L/437 (2006.01) Johnson, Moraga, CA (US) C07D 47L/04 (2006.01) Correspondence Address: C07D 413/14 (2006.01) King & Spalding LLP A 6LX 3/5.377 (2006.01) P.O. BOX 889 A6IP II/06 (2006.01) Belmont, CA 94002-0889 (US) (52) U.S. Cl. ...................... 514/233.2:546/121; 544/127; (21) Appl. No.: 12/482,307 514/3OO (22) Filed: Jun. 10, 2009 Related U.S. Application Data (57) ABSTRACT (62) Division of application No. 1 1/810,885, filed on Jun. 6, The present invention is directed to substituted pyrazolo 1.5- 2007, now Pat. No. 7,585,875. apyridines and related methods for their synthesis and use. Patent Application Publication Dec. 24, 2009 Sheet 1 of 2 US 2009/0318437 A1 log threshold withdrawal (mg x 10) s s t | yme as w (s (f) pouseul emerpum 909 Y Patent Application Publication Dec. 24, 2009 Sheet 2 of 2 US 2009/0318437 A1 s o O O war C SSm S.t c) is . E E C C a S. & S. is 25 &(2 52 > w- we t : : log threshold withdrawal (mg x 10) N CN N.
    [Show full text]
  • SIGHI-Leaflet Histamine Elimination Diet Simplified Histamine Elimination Diet for Histamine Intolerance (DAO Degradation Disorder)
    Version 2020-07-20 SIGHI-Leaflet Histamine Elimination Diet Simplified histamine elimination diet for histamine intolerance (DAO degradation disorder) For people with a DAO degradation disorder The compatibility is highly dependent on the in- who have to avoid histamine, other biogenic dividual sensitivity and the amount consumed. amines and DAO inhibitors in their diet. Furthermore, it is temporarily affected by stress, In case of histamine sensitivity due to mast cell hormones and many other factors. First and activation disorders (MCAD) this dietary guide- foremost, the freshness is an important cri- line is not sufficient! If no permanent symptom terion. Everybody has to find out by trial and er- relief can be achieved and maintained with this ror what he/she can tolerate in what quantities. diet, please follow the detailed list, which addi- At the beginning of the experimental diet this list tionally takes histamine liberators into consid- should be followed as consistently as possible. eration as completely as possible. It is available In a later stage, however, the diet should be here: based more on the experiences of the person www.mastzellaktivierung.info concerned rather than following any list. Mast cell activation disorders are often mistaken Always read the list of ingredients to find out for histamine intolerance. whether a food contains incompatible ingredi- ents. References: • Experience reports from among our members and readers • Various patient leaflets from doctors, clinics and hospitals • Experience of other patient organizations, bloggers, forum threads etc. • Scientific publications • Textbooks and cookbooks about histamine intolerance To avoid: ? Risky: Well tolerated: Fermented or microbially ripened Meals from res- Prefer fresh, unprocessed or little pro- products (e.g.
    [Show full text]
  • THE USE of MIRTAZAPINE AS a HYPNOTIC O Uso Da Mirtazapina Como Hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa
    ARTIGO ESPECIAL THE USE OF MIRTAZAPINE AS A HYPNOTIC O uso da mirtazapina como hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa Prescription of approved hypnotics for insomnia decreased by more than 50%, whereas of antidepressive agents outstripped that of hypnotics. However, there is little data on their efficacy to treat insomnia, and many of these medications may be associated with known side effects. Antidepressants are associated with various effects on sleep patterns, depending on the intrinsic pharmacological properties of the active agent, such as degree of inhibition of serotonin or noradrenaline reuptake, effects on 5-HT1A and 5-HT2 receptors, action(s) at alpha-adrenoceptors, and/or histamine H1 sites. Mirtazapine is a noradrenergic and specific serotonergic antidepressive agent that acts by antagonizing alpha-2 adrenergic receptors and blocking 5-HT2 and 5-HT3 receptors. It has high affinity for histamine H1 receptors, low affinity for dopaminergic receptors, and lacks anticholinergic activity. In spite of these potential beneficial effects of mirtazapine on sleep, no placebo-controlled randomized clinical trials of ABSTRACT mirtazapine in primary insomniacs have been conducted. Mirtazapine was associated with improvements in sleep on normal sleepers and depressed patients. The most common side effects of mirtazapine, i.e. dry mouth, drowsiness, increased appetite and increased body weight, were mostly mild and transient. Considering its use in elderly people, this paper provides a revision about studies regarding mirtazapine for sleep disorders. KEYWORDS: sleep; antidepressive agents; sleep disorders; treatment� A prescrição de hipnóticos aprovados para insônia diminuiu em mais de 50%, enquanto de antidepressivos ultrapassou a dos primeiros.
    [Show full text]
  • Synthesis, Characterization and in Vitro Antimicrobial
    Journal of Saudi Chemical Society (2011) xxx, xxx–xxx King Saud University Journal of Saudi Chemical Society www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Synthesis, characterization and in vitro antimicrobial activity of some 1-(substitutedbenzylidene) -4-(4-(2-(methyl/phenyl)-4-oxoquinazolin-3(4H)- yl)phenyl)semicarbazide derivatives Govindaraj Saravanan a,*, Veerachamy Alagarsamy b, Chinnasamy Rajaram Prakash c a Medicinal Chemistry Research Laboratory, Bapatla College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Andhra Pradesh, India b Medicinal Chemistry Research Laboratory, M.N.R. College of Pharmacy, Sangareddy, Andhra Pradesh, India c Department of Medicinal Chemistry, DCRM Pharmacy College, Inkollu, Andhra Pradesh, India Received 19 October 2011; accepted 6 December 2011 KEYWORDS Abstract A series of 1-(substitutedbenzylidene)-4-(4-(2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl) Quinazolin-4(3H)-one; phenyl)semicarbazide derivatives were synthesized with the aim of developing potential antimicro- Semicarbazide; bials. It was characterized by FT-IR, 1H NMR, Mass spectroscopy and elemental analysis. In addi- Schiff base; tion, the in vitro antibacterial and antifungal properties were tested against some human pathogenic Antibacterial activity; microorganisms by employing the disc diffusion technique and agar streak dilution method. All title Antifungal activity compounds showed activity against the entire strain of microorganisms. The relationship between the functional group variation and the biological activity of the evaluated compounds were well dis- cussed. Based on the results obtained, compound 5j was found to be very active compared to the rest of the compounds which were subjected to antimicrobial assay. ª 2011 King Saud University. Production and hosting by Elsevier B.V.
    [Show full text]
  • Step-By-Step Guide to Better Laboratory Management Practices
    Step-by-Step Guide to Better Laboratory Management Practices Prepared by The Washington State Department of Ecology Hazardous Waste and Toxics Reduction Program Publication No. 97- 431 Revised January 2003 Printed on recycled paper For additional copies of this document, contact: Department of Ecology Publications Distribution Center PO Box 47600 Olympia, WA 98504-7600 (360) 407-7472 or 1 (800) 633-7585 or contact your regional office: Department of Ecology’s Regional Offices (425) 649-7000 (509) 575-2490 (509) 329-3400 (360) 407-6300 The Department of Ecology is an equal opportunity agency and does not discriminate on the basis of race, creed, color, disability, age, religion, national origin, sex, marital status, disabled veteran’s status, Vietnam Era veteran’s status or sexual orientation. If you have special accommodation needs, or require this document in an alternate format, contact the Hazardous Waste and Toxics Reduction Program at (360)407-6700 (voice) or 711 or (800) 833-6388 (TTY). Table of Contents Introduction ....................................................................................................................................iii Section 1 Laboratory Hazardous Waste Management ...........................................................1 Designating Dangerous Waste................................................................................................1 Counting Wastes .......................................................................................................................8 Treatment by Generator...........................................................................................................12
    [Show full text]
  • Gabaergic Mechanisms of Anterior and Ventromedial Hypothalamic
    PSYCHOLOGY Psychology & Neuroscience, 2011, 4, 2, 211 - 217 NEUROSCIENCE DOI: 10.3922/j.psns.2011.2.006 GABAergic mechanisms of anterior and ventromedial hypothalamic nuclei in the expression of freezing in response to a light-conditioned stimulus Julia Maria dos Santos1 and Marcus Lira Brandão2 1 - Instituto de Neurociências & Comportamento - INeC, Ribeirão Preto, SP, Brasil 2 - Universidade de São Paulo, Ribeirão Preto, SP, Brasil Abstract The amygdala, dorsal periaqueductal gray (dPAG), and medial hypothalamus have long been recognized to comprise a neural system responsible for the generation and elaboration of unconditioned fear in the brain. This neural substrate is well known to be under tonic inhibitory control exerted by γ-aminobutyric acid (GABA) mechanisms. Some evidence also suggests that these structures integrate conditioned fear. A recent study using the fear-potentiated startle paradigm showed that GABAergic mechanisms in the anterior hypothalamic nucleus (AHN) and dorsomedial part of the ventromedial hypothalamic nucleus (VMHDM) regulate conditioned fear. The present study examined the extent to which GABAergic mechanisms in these brain regions are involved in conditioned fear by measuring freezing in response to a light used as a conditioned stimulus (CS). The GABAA receptor agonist muscimol and the GABA-synthesizing enzyme glutamic acid decarboxylase inhibitor semicarbazide were used as an enhancer and inhibitor of GABA mechanisms, respectively. Muscimol and semicarbazide were injected into the AHN or VMHDM of rats before fear conditioning. Muscimol injections into the AHN and VMHDM significantly reduced conditioned freezing, whereas inhibition of GABA transmission increased this conditioned response in the AHN. The present study further supports the hypothesis that GABAergic mechanisms in the AHN and VMHDM exert inhibitory control on the neural substrates of conditioned fear in the hypothalamus.
    [Show full text]
  • United States Patent Office Patented Aug
    3,461,106 United States Patent Office Patented Aug. 12, 1969 1. 2 have insufficient fastness, frequently accompanied by 3,461,106 PGLYURETHANE FBERS insufficient absorption rates and depth of colour of the Harald Oertel and Heinrich Rinke, Leverkusen, Wilhelm dyeings, factors which also have a negative effect on the Thoma, Cologne-Flittard, and Friedrich-Karl Rosen fastness of such dyeings to abrasion. Further, the over dahl, Leverkusen-Schlebusch, Germany, assignors to dyeing properties are in many cases inadequate owing Farbenfabriken Bayer Aktiengeseischaft, Leverkusen, to the poor wash fastness of the dyeings. If, however, Germany, a corporation of Germany polyurethane elastomer fibres are to be widely used No Drawing. Fied May 21, 1965, Ser. No. 457,800 for textile purposes, the obtaining of deep and fast dye Claims priority, application Germany, May 23, 1964, ings is essential. This applies especially to the use of F 42,970 important groups of dyes such as acid dyes, metal com int. C. C08g 22/04, 22/06 O plex dyes or chrome dyes with which fast dyeings in U.S. C. 260-75 11 Claims deep colour tones can be obtained e.g. on polyamides which are used preferentially in conjunction with elastic polyurethane threads. The stability of polyurethane ABSTRACT OF THE DISCLOSURE 5 elastomer threads and foils to discolouration in light and Segmented polyurethane elastomers having improved to yellowing under the effect of atmospheric waste gases dyeability containing a repeating unit and having at least (especially nitrous gases and waste gases of combustion) one carboxylic acid hydrazide grouping and at least one still leaves room for improvement.
    [Show full text]
  • On the Extraction of Antibiotics from Shrimps Prior to Chromatographic Analysis
    separations Review On the Extraction of Antibiotics from Shrimps Prior to Chromatographic Analysis Victoria Samanidou *, Dimitrios Bitas, Stamatia Charitonos and Ioannis Papadoyannis Laboratory of Analytical Chemistry, University of Thessaloniki, GR 54124 Thessaloniki, Greece; [email protected] (D.B.); [email protected] (S.C.); [email protected] (I.P.) * Correspondence: [email protected]; Tel.: +30-2310-997698; Fax: +30-2310-997719 Academic Editor: Frank L. Dorman Received: 2 February 2016; Accepted: 26 February 2016; Published: 4 March 2016 Abstract: The widespread use of antibiotics in veterinary practice and aquaculture has led to the increase of antimicrobial resistance in food-borne pathogens that may be transferred to humans. Global concern is reflected in the regulations from different agencies that have set maximum permitted residue limits on antibiotics in different food matrices of animal origin. Sensitive and selective methods are required to monitor residue levels in aquaculture species for routine regulatory analysis. Since sample preparation is the most important step, several extraction methods have been developed. In this review, we aim to summarize the trends in extraction of several antibiotics classes from shrimps and give a comparison of performance characteristics in the different approaches. Keywords: sample preparation; extraction; aquaculture; shrimps; chromatography; antibiotics 1. Introduction According to FAO (CWP Handbook of Fishery Statistical Standards, Section J: AQUACULTURE), “aquaculture is the farming of aquatic organisms: fish, mollusks, crustaceans, aquatic plants, crocodiles, alligators, turtles, and amphibians. Farming implies some form of intervention in the rearing process to enhance production, such as regular stocking, feeding, protection from predators, etc.”[1]. Since 1960, aquaculture practice and production has increased as a result of the improved conditions in the aquaculture facilities.
    [Show full text]
  • Histamine and Antihistamines Sites of Action Conditions Which Cause Release Aron H
    Learning Objectives I Histamine Pharmacological effects Histamine and Antihistamines Sites of action Conditions which cause release Aron H. Lichtman, Ph.D. Diagnostic uses Associate Professor II Antihistamines acting at the H1 and H2 receptor Pharmacology and Toxicology Pharmacological effects Mechanisms of action Therapeutic uses Side effects and drug interactions Be familiar with the existence of the H3 receptor III Be able to describe the main mechanism of action of cromolyn sodium and its clinical uses Histamine Pharmacology First autacoid to be discovered. (Greek: autos=self; Histamine Formation akos=cure) Synthesized in 1907 Synthesized in mammalian tissues by Demonstrated to be a natural constituent of decarboxylation of the amino acid l-histidine mammalian tissues (1927) Involved in inflammatory and anaphylactic reactions. Local application causes swelling redness, and edema, mimicking a mild inflammatory reaction. Large systemic doses leads to profound vascular changes similar to those seen after shock or anaphylactic origin Histamine Stored in complex with: Heparin Chondroitin Sulfate Eosinophilic Chemotactic Factor Neutrophilic Chemotactic Factor Proteases 1 Conditions That Release Histamine 1. Tissue injury: Any physical or chemical agent that injures tissue, skin or mucosa are particularly sensitive to injury and will cause the immediate release of histamine from mast cells. 2. Allergic reactions: exposure of an antigen to a previously sensitized (exposed) subject can immediately trigger allergic reactions. If sensitized by IgE antibodies attached to their surface membranes will degranulate when exposed to the appropriate antigen and release histamine, ATP and other mediators. 3. Drugs and other foreign compounds: morphine, dextran, antimalarial drugs, dyes, antibiotic bases, alkaloids, amides, quaternary ammonium compounds, enzymes (phospholipase C).
    [Show full text]
  • Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders
    Neuropsychopharmacology (2003) 28, 402–412 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders ,1 2 3 2 Gerard J Marek* , Linda L Carpenter , Christopher J McDougle and Lawrence H Price 1Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; 2Department of Psychiatry and Human, Brown Medical School, Mood 3 Disorders Program, Behavior, Butler Hospital, Providence, RI, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA Recently, the addition of drugs with prominent 5-HT2 receptor antagonist properties (risperidone, olanzapine, mirtazapine, and mianserin) to selective serotonin reuptake inhibitors (SSRIs) has been shown to enhance therapeutic responses in patients with major depression and treatment-refractory obsessive–compulsive disorder (OCD). These 5-HT antagonists may also be effective in 2 ameliorating some symptoms associated with autism and other pervasive developmental disorders (PDDs). At the doses used, these drugs would be expected to saturate 5-HT2A receptors. These findings suggest that the simultaneous blockade of 5-HT2A receptors and activation of an unknown constellation of other 5-HT receptors indirectly as a result of 5-HT uptake inhibition might have greater therapeutic efficacy than either action alone. Animal studies have suggested that activation of 5-HT1A and 5-HT2C receptors may counteract the effects of activating 5-HT2A receptors. Additional 5-HT receptors, such as the 5-HT1B/1D/5/7 receptors, may similarly counteract the effects of 5-HT receptor activation. These clinical and preclinical observations suggest that the combination of highly 2A selective 5-HT antagonists and SSRIs, as well as strategies to combine high-potency 5-HT receptor and 5-HT transporter blockade in 2A 2A a single compound, offer the potential for therapeutic advances in a number of neuropsychiatric disorders.
    [Show full text]
  • Assessment Report
    19 September 2013 EMA/737723/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report ABILIFY MAINTENA International non-proprietary name: ARIPIPRAZOLE Procedure No. EMEA/H/C/002755/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Table of contents 1.1. Submission of the dossier .................................................................................... 6 1.2. Manufacturers ................................................................................................... 6 1.3. Steps taken for the assessment of the product ....................................................... 7 2. Scientific discussion ................................................................................ 7 2.1. Introduction ...................................................................................................... 7 2.2. Quality aspects .................................................................................................. 9 2.2.1. Introduction ................................................................................................... 9 2.2.2. Active Substance ..........................................................................................
    [Show full text]